Phil's Power Pancakes In All 5 Varieties Recalled

fda nov21 lt

Costa Mesa, California-based Phil's Power Pancake is recalling its pancakes in all 5 varieties citing possible presence of undeclared wheat, the U.S. Food and Drug Administration said.

The recalled pancakes come in Mango, Raspberry, Cranberry, Dates, and Chocolate Chip Hempseed varieties. They are individually wrapped in clear 5 oz. plastic packages labeled with UPC Code 8 37654 48372 5. All product currently on the market is subject to recall.

Phil's Power Pancakes are distributed locally in Orange County & Los Angeles, California at various gyms and markets in refrigerated cases.

All 5 varieties of pancakes contain rye flour that contains 1% wheat. Labels on the product distributed state "wheat free" and new labels will read "99% wheat free".

The agency noted that people who have an allergy or severe sensitivity to wheat may get serious or life-threatening allergic reaction if they consume these products.

However, no illnesses have been reported to date in connection with the recalled product.

Consumers who have purchased 5 oz. packages of Phil's Power Pancakes are urged to return them to the place of purchase for a full refund.

In similar recalls, TreeHouse Foods, Inc. in September called back one lot of restaurant style Italian dressing sold under the brand name Tuscan Garden due to undeclared wheat and soy.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT